AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by equities research analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Friday.
Other equities analysts also recently issued research reports about the stock. BNP Paribas reaffirmed a “neutral” rating and set a GBX 5,300 ($69.21) price target on shares of AstraZeneca plc in a research note on Monday, April 3rd. UBS AG set a GBX 5,150 ($67.25) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a research note on Wednesday, April 5th. HSBC Holdings plc reaffirmed a “reduce” rating and set a GBX 4,200 ($54.84) price target on shares of AstraZeneca plc in a research note on Friday, May 5th. Shore Capital reaffirmed a “sell” rating on shares of AstraZeneca plc in a research note on Wednesday, May 10th. Finally, Berenberg Bank raised their price target on shares of AstraZeneca plc from GBX 5,670 ($74.04) to GBX 5,850 ($76.39) and gave the company a “buy” rating in a research note on Wednesday, May 17th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of GBX 5,251.80 ($68.58).
Shares of AstraZeneca plc (AZN) opened at 5152.00 on Friday. The firm’s market capitalization is GBX 65.22 billion. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 5,235.89 and a 200 day moving average price of GBX 4,847.81.
COPYRIGHT VIOLATION WARNING: “J P Morgan Chase & Co Reiterates “Neutral” Rating for AstraZeneca plc (AZN)” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://transcriptdaily.com/2017/07/23/j-p-morgan-chase-co-reiterates-neutral-rating-for-astrazeneca-plc-azn.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.